Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
Major surgery in the last 3 months prior to baseline or planned major surgery or cardiac intervention during the study.
Cancer or other significant co-morbidities implying that the patient's condition is unstable.
Comorbidities that can be associated with elevated natriuretic peptide (NP) levels: renal insufficiency, (eGFR < 25 ml/min/1.73 mÂ² calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months.
Patients who are primarily managed and regularly followed-up by a cardiologist for their HF
Highly frail patients whose estimated lifespan due to comorbidities by the judgement of the investigator is less than 6 months.
